Oragenics (NYSEMKT:OGEN) stock is falling on Wednesday after the antibiotics development company announced details of a public offering for its shares.
Oragenics is selling 1.4 million shares of OGEN stock for $1.50 each. The company is also allowing underwriters ThinkEquity and Laidlaw & Company (UK) Ltd. to purchase another 210,000 shares at the public offering price.
Oragenics is expecting to raise gross proceeds of $2.1 million from this public offering. It says it will use these funds to fuel its continued development of ONP-002. This is its neurosteroid drug compound designed to treat mild traumatic brain injuries. The money will also go toward general corporate purposes and working capital.
How This Affects OGEN Stock
A public stock offering increases the total number of OGEN shares on the market. That means it also dilutes the stakes of current investors in the company. This is one of the reasons shares are down today.
Adding to that is the public offering price of $1.50 per share. Investors will note that’s a strong discount compared to its prior closing price of $2.45. That’s another reason shares of OGEN are falling today.
OGEN stock is down 45.3% as of Wednesday morning as some 348,000 shares change hands. That’s already well above its daily average trading volume of about 37,000 shares.
Investors who want to dive into even more of the most recent stock market stories this morning are in luck!
We’re offering all of the hottest stock market coverage traders need to know about on Wednesday! A few examples include why Beyond Meat (NASDAQ:BYND) and Nauticus Robotics (NASDAQ:KITT) stock are up today, as well as a look at our stock pick of the day. You can find out more on these matters at the following links!
More Wednesday Stock Market News
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
